Expert consensus on the use of systemic glucocorticoids for managing eosinophil-related diseases
Eosinophil-related diseases represent a group of pathologic conditions with highly heterogeneous clinical presentation and symptoms ranging from mild to critical. Both systemic and localized forms of disease are typically treated with glucocorticoids. The approval of novel biologic therapies targeti...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-01-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1310211/full |
| _version_ | 1797365573417435136 |
|---|---|
| author | Victoria del Pozo Irina Bobolea Manuel J. Rial Manuel J. Rial Georgina Espigol-Frigolé Roser Solans Laqué Jesús María Hernández-Rivas Elvira Mora Astrid Crespo-Lessmann José Luis Izquierdo Alonso José Luis Izquierdo Alonso María Sandra Domínguez Sosa Juan Maza-Solano Belén Atienza-Mateo David Bañas-Conejero Abraham L. Moure Íñigo Rúa-Figueroa |
| author_facet | Victoria del Pozo Irina Bobolea Manuel J. Rial Manuel J. Rial Georgina Espigol-Frigolé Roser Solans Laqué Jesús María Hernández-Rivas Elvira Mora Astrid Crespo-Lessmann José Luis Izquierdo Alonso José Luis Izquierdo Alonso María Sandra Domínguez Sosa Juan Maza-Solano Belén Atienza-Mateo David Bañas-Conejero Abraham L. Moure Íñigo Rúa-Figueroa |
| author_sort | Victoria del Pozo |
| collection | DOAJ |
| description | Eosinophil-related diseases represent a group of pathologic conditions with highly heterogeneous clinical presentation and symptoms ranging from mild to critical. Both systemic and localized forms of disease are typically treated with glucocorticoids. The approval of novel biologic therapies targeting the interleukin-5 pathway can help reduce the use of systemic glucocorticoids (SGC) in eosinophilic diseases and reduce the risk of SGC-related adverse effects (AEs). In this article, a panel of experts from different medical specialties reviewed current evidence on the use of SGC in two systemic eosinophilic diseases: Eosinophilic Granulomatosis with PolyAngiitis (EGPA) and HyperEosinophilic Syndrome (HES); and in two single-organ (respiratory) eosinophilic diseases: Chronic RhinoSinusitis with Nasal Polyps (CRSwNP) and Severe Asthma with Eosinophil Phenotype (SA-EP), and contrasted it with their experience in clinical practice. Using nominal group technique, they reached consensus on key aspects related to the dose and tapering of SGC as well as on the initiation of biologics as SGC-sparing agents. Early treatment with biologics could help prevent AEs associated with medium and long-term use of SGC. |
| first_indexed | 2024-03-08T16:50:56Z |
| format | Article |
| id | doaj.art-4c7961b8003248b7b8aa47cd17031178 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-03-08T16:50:56Z |
| publishDate | 2024-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-4c7961b8003248b7b8aa47cd170311782024-01-05T04:30:59ZengFrontiers Media S.A.Frontiers in Immunology1664-32242024-01-011410.3389/fimmu.2023.13102111310211Expert consensus on the use of systemic glucocorticoids for managing eosinophil-related diseasesVictoria del Pozo0Irina Bobolea1Manuel J. Rial2Manuel J. Rial3Georgina Espigol-Frigolé4Roser Solans Laqué5Jesús María Hernández-Rivas6Elvira Mora7Astrid Crespo-Lessmann8José Luis Izquierdo Alonso9José Luis Izquierdo Alonso10María Sandra Domínguez Sosa11Juan Maza-Solano12Belén Atienza-Mateo13David Bañas-Conejero14Abraham L. Moure15Íñigo Rúa-Figueroa16Immunology Department, Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD), Madrid, SpainAllergy Department, Severe Asthma Unit, Hospital Clínic Barcelona, Barcelona, SpainAllergy Department, Severe Asthma Unit, Complexo Hospitalario Universitario A Coruña, A Coruña, SpainCentro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), A Coruña, SpainDepartment of Autoimmune Diseases, Hospital Clinic Clínic, University of Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, SpainAutoimmune Systemic Diseases Unit, Internal Medicine Department, Vall d’Hebron Hospital, Autonomous University of Barcelona, Barcelona, SpainDepartment of Medicine, University of Salamanca & Servicio de Hematología, Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, SpainHematology Department, La Fe University and Polytechnic Hospital, La Fe Research Institute, Valencia, SpainDepartment of Respiratory Medicine, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain0Department of Medicine and Medical Specialties, University of Alcalá, Alcalá de Henares, Madrid, Spain1Pulmonology Service, Guadalajara University Hospital, Guadalajara, Spain2Rhinology Unit, Department of Otolaryngology, Head and Neck Surgery, University Hospital of Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain3Rhinology Unit, Department of Otolaryngology, Head and Neck Surgery, Virgen Macarena University Hospital, Sevilla, Spain4Division of Rheumatology, University Hospital of Marqués de Valdecilla, Instituto de Investigación Marqués de Valdecilla (IDIVAL), Immunopathology group, Santander, Spain5Specialty Care Medical Department, GSK, Madrid, Spain5Specialty Care Medical Department, GSK, Madrid, Spain6Rheumatology Department, University Hospital of Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, SpainEosinophil-related diseases represent a group of pathologic conditions with highly heterogeneous clinical presentation and symptoms ranging from mild to critical. Both systemic and localized forms of disease are typically treated with glucocorticoids. The approval of novel biologic therapies targeting the interleukin-5 pathway can help reduce the use of systemic glucocorticoids (SGC) in eosinophilic diseases and reduce the risk of SGC-related adverse effects (AEs). In this article, a panel of experts from different medical specialties reviewed current evidence on the use of SGC in two systemic eosinophilic diseases: Eosinophilic Granulomatosis with PolyAngiitis (EGPA) and HyperEosinophilic Syndrome (HES); and in two single-organ (respiratory) eosinophilic diseases: Chronic RhinoSinusitis with Nasal Polyps (CRSwNP) and Severe Asthma with Eosinophil Phenotype (SA-EP), and contrasted it with their experience in clinical practice. Using nominal group technique, they reached consensus on key aspects related to the dose and tapering of SGC as well as on the initiation of biologics as SGC-sparing agents. Early treatment with biologics could help prevent AEs associated with medium and long-term use of SGC.https://www.frontiersin.org/articles/10.3389/fimmu.2023.1310211/fulladverse eventseosinophilic diseasessystemic glucocorticoidsbiologicstaperingtreatment optimisation |
| spellingShingle | Victoria del Pozo Irina Bobolea Manuel J. Rial Manuel J. Rial Georgina Espigol-Frigolé Roser Solans Laqué Jesús María Hernández-Rivas Elvira Mora Astrid Crespo-Lessmann José Luis Izquierdo Alonso José Luis Izquierdo Alonso María Sandra Domínguez Sosa Juan Maza-Solano Belén Atienza-Mateo David Bañas-Conejero Abraham L. Moure Íñigo Rúa-Figueroa Expert consensus on the use of systemic glucocorticoids for managing eosinophil-related diseases Frontiers in Immunology adverse events eosinophilic diseases systemic glucocorticoids biologics tapering treatment optimisation |
| title | Expert consensus on the use of systemic glucocorticoids for managing eosinophil-related diseases |
| title_full | Expert consensus on the use of systemic glucocorticoids for managing eosinophil-related diseases |
| title_fullStr | Expert consensus on the use of systemic glucocorticoids for managing eosinophil-related diseases |
| title_full_unstemmed | Expert consensus on the use of systemic glucocorticoids for managing eosinophil-related diseases |
| title_short | Expert consensus on the use of systemic glucocorticoids for managing eosinophil-related diseases |
| title_sort | expert consensus on the use of systemic glucocorticoids for managing eosinophil related diseases |
| topic | adverse events eosinophilic diseases systemic glucocorticoids biologics tapering treatment optimisation |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1310211/full |
| work_keys_str_mv | AT victoriadelpozo expertconsensusontheuseofsystemicglucocorticoidsformanagingeosinophilrelateddiseases AT irinabobolea expertconsensusontheuseofsystemicglucocorticoidsformanagingeosinophilrelateddiseases AT manueljrial expertconsensusontheuseofsystemicglucocorticoidsformanagingeosinophilrelateddiseases AT manueljrial expertconsensusontheuseofsystemicglucocorticoidsformanagingeosinophilrelateddiseases AT georginaespigolfrigole expertconsensusontheuseofsystemicglucocorticoidsformanagingeosinophilrelateddiseases AT rosersolanslaque expertconsensusontheuseofsystemicglucocorticoidsformanagingeosinophilrelateddiseases AT jesusmariahernandezrivas expertconsensusontheuseofsystemicglucocorticoidsformanagingeosinophilrelateddiseases AT elviramora expertconsensusontheuseofsystemicglucocorticoidsformanagingeosinophilrelateddiseases AT astridcrespolessmann expertconsensusontheuseofsystemicglucocorticoidsformanagingeosinophilrelateddiseases AT joseluisizquierdoalonso expertconsensusontheuseofsystemicglucocorticoidsformanagingeosinophilrelateddiseases AT joseluisizquierdoalonso expertconsensusontheuseofsystemicglucocorticoidsformanagingeosinophilrelateddiseases AT mariasandradominguezsosa expertconsensusontheuseofsystemicglucocorticoidsformanagingeosinophilrelateddiseases AT juanmazasolano expertconsensusontheuseofsystemicglucocorticoidsformanagingeosinophilrelateddiseases AT belenatienzamateo expertconsensusontheuseofsystemicglucocorticoidsformanagingeosinophilrelateddiseases AT davidbanasconejero expertconsensusontheuseofsystemicglucocorticoidsformanagingeosinophilrelateddiseases AT abrahamlmoure expertconsensusontheuseofsystemicglucocorticoidsformanagingeosinophilrelateddiseases AT inigoruafigueroa expertconsensusontheuseofsystemicglucocorticoidsformanagingeosinophilrelateddiseases |